FDA Inspection 1236675 — Bristol-Myers Squibb Pharmaceuticals Limited
The FDA completed an inspection of Bristol-Myers Squibb Pharmaceuticals Limited on May 10, 2023 in Wirral. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- May 10, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wirral (United Kingdom)
Additional Details
Mutual Recognition Agreement (MRA)